Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic and orthopedic markets. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic or orthopedic industry newsletters.

Recently Added

1/26/2021
COVID-19IndustryNewsletterOphthalmicSurgery
2020 in Review: COVID-19 Derails Ophthalmology’s Hopes for Year Celebrating 20/20 Vision
2020 in Review: COVID-19 Derails Ophthalmology’s Hopes for Year Celebrating 20/20 Vision

Many ophthalmic companies and practices entered 2020 seeing the date as a marketing gift to promote all things related to quality vision. It was to be a banner year. 2020 ended with the number perm...

1/26/2021
CataractIOLNewsletterOphthalmic
Alcon Vivity Launch Expected to Expand PC-IOLs’ Market Share in US
Alcon Vivity Launch Expected to Expand PC-IOLs’ Market Share in US

Alcon on Jan. 7 announced the commercial launch of the AcrySof IQ Vivity non-diffractive extended depth of focus (EDOF) IOL, including a toric version, in the US. We project the Vivity will help dr...

1/26/2021
DealsFundingNewsletterOphthalmic
Ophthalmic Fundraising Activity Soars in the Face of Global Pandemic
Ophthalmic Fundraising Activity Soars in the Face of Global Pandemic

The ophthalmic market continues to expand and attract funding from investors. There were more deals in 2020 than the two previous years, and transactions totaled $8.6 billion. Retina is the largest...

1/26/2021
Dry EyeNewsletterOphthalmicPharma
Kala Launches Eysuvis for Short-Term Treatment of Dry Eye
Kala Launches Eysuvis for Short-Term Treatment of Dry Eye

Kala Pharmaceuticals announced Jan. 7 that it had launched Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dr...

1/26/2021
AcquisitionsDealsNewsletterOphthalmicRetina
Pixium, Second Sight to Combine Operations, with New Company Trading on Nasdaq
Pixium, Second Sight to Combine Operations, with New Company Trading on Nasdaq

French company Pixium Vision and Second Sight Medical Products, of California, announced Jan. 6 that the two would combine operations. Pixium will contribute to Second Sight all of its assets and l...

1/26/2021
NewsletterOphthalmicRegulation
US Regulatory Roundup: Ophthalmologists Now to See Increase in 2021
US Regulatory Roundup: Ophthalmologists Now to See Increase in 2021

A US spending package signed into law on Dec. 27 erased the impact of Medicare’s negative physician fee adjustments for eye care providers in 2021. Ophthalmologists were prepared to see an average ...

1/26/2021
DeviceNewsletterOphthalmicRegulation
US FDA PMA Approvals and 510(k) Clearances for December 2020
US FDA PMA Approvals and 510(k) Clearances for December 2020

The US FDA’s ophthalmic devices division granted four clearances through the 510(k) pathway in December 2020, according to the agency’s database. One involved adding an indication for use to an alr...

1/26/2021
COVID-19IndustryNewsletterOphthalmicSurgery
2020 in Review: Corporate, Surgeon Picks for Top Stories
2020 in Review: Corporate, Surgeon Picks for Top Stories

Market Scope polled companies and practices to rank our list of top 10 ophthalmic stories for 2020. Not surprisingly, both groups chose the COVID-19 pandemic as the No. 1 story. Corporate participa...

1/26/2021
CataractIOLNewsletterOphthalmic
2020 in Review: Premium IOL Options Increased Worldwide, Despite Pandemic
2020 in Review: Premium IOL Options Increased Worldwide, Despite Pandemic

A steady flow of premium IOLs debuted in markets throughout the world in 2020, despite the pandemic. Evidence continues to show that trifocal IOLs are becoming the most popular presbyopia-correctin...

1/26/2021
NewsletterOphthalmicPharmaRetina
2020 in Review: Safety Concerns Trip Up Anticipated New Anti-VEGF Drugs
2020 in Review: Safety Concerns Trip Up Anticipated New Anti-VEGF Drugs

“Safety first” sums up the year 2020 in retina as retina specialists and regulators handed surprise setbacks to two highly anticipated new drugs for wet age-related macular degeneration. A safety n...

1/26/2021
NewsletterOphthalmicPharmaPresbyopia
2020 in Review: Interest in Presbyopia Eye Drops Continues to Expand
2020 in Review: Interest in Presbyopia Eye Drops Continues to Expand

Discussion surrounding eye drop solutions for presbyopia ramped up in 2020. Drug formulations are aimed at modifying factors involved in the accommodative process. These compounds are in various st...

1/26/2021
CataractNewsletterOphthalmicSurgical
2020 in Review: Industry Sees Renewed Investment in FLACS in 2020
2020 in Review: Industry Sees Renewed Investment in FLACS in 2020

2020 saw renewed development interest and activity in femtosecond laser-assisted cataract surgery (FLACS) technology, after years of minimal investment. Companies took steps—both incremental and su...

Past News Stories

1/26/2021
DeviceGlaucomaNewsletterOphthalmic
2020 in Review: Glaucoma Specialists Gain Clarity on Surgical Options for Advanced Cases
2020 in Review: Glaucoma Specialists Gain Clarity on Surgical Options for Advanced Cases

US glaucoma specialists in 2020 gained clarity on their options for surgically treating patients with more advanced stages of glaucoma, including MIGS devices with greater efficacy, additional ways...

1/26/2021
GlaucomaNewsletterOphthalmicPharma
2020 in Review: Durysta Becomes First Sustained-Release Drug Implant for Glaucoma
2020 in Review: Durysta Becomes First Sustained-Release Drug Implant for Glaucoma

The long-anticipated era of sustained drug delivery in glaucoma finally arrived in 2020, if not exactly with a bang, then not with a whimper either. Durysta, a 10-microgram bimatoprost implant from...

1/26/2021
COVID-19MeetingNewsletterOphthalmic
2020 in Review: Ophthalmic Groups Learn on the Fly in Shift to Virtual Meetings
2020 in Review: Ophthalmic Groups Learn on the Fly in Shift to Virtual Meetings

The COVID-19 pandemic forced ophthalmic associations around the world to cancel in-person conferences in 2020 and go online. Groups putting on virtual conferences were learning as they went. Along ...

1/26/2021
CornealNewsletterOphthalmic
2020 in Review: Disruptive Cornea Products Could Help Bridge Transplant Gap
2020 in Review: Disruptive Cornea Products Could Help Bridge Transplant Gap

Synthetic cornea transplant solutions hit major milestones in 2020 on the path toward market approval. These products have the potential to disrupt the cornea landscape and address a critically unm...

1/26/2021
DealsNewsletterOphthalmic
2020 in Review: Ophthalmic Firms Expand Portfolios, Despite Pandemic
2020 in Review: Ophthalmic Firms Expand Portfolios, Despite Pandemic

Acquisitions and other deals continued at a rapid pace in 2020, in spite of the pandemic or perhaps as a result of it. No deal stood out as an ophthalmic industry blockbuster. Top companies gobbled...

1/26/2021
COVID-19NewsletterOphthalmic
$38.2 Billion Ophthalmic Market Has Plenty of Room for Innovation
$38.2 Billion Ophthalmic Market Has Plenty of Room for Innovation

The traditional “Big Three” ophthalmic companies—Alcon, Bausch + Lomb, and J&J Vision—have dominated industry meetings, marketed broad product lines, and held the widest global reach, but the ophth...

1/26/2021
NewsletterOphthalmicRetina
Trump Commutes Medicare Fraud Sentence of Former Retina Specialist Melgen
Trump Commutes Medicare Fraud Sentence of Former Retina Specialist Melgen

Former retina specialist Salomon Melgen was among 70 people whose sentences were commuted by President Donald Trump early on Jan. 20 in the waning hours of his term. Melgen, 66, of Florida, was sen...

1/26/2021
Dry EyeFundingGlaucomaLaserNewsletterOphthalmicRetina
NGM Bio Leads Latest Fundraising Efforts with $125 Million Public Offering
NGM Bio Leads Latest Fundraising Efforts with $125 Million Public Offering

NGM Biopharmaceuticals, of South San Francisco, California, led recent fundraising efforts by ophthalmic companies, with a $125 million underwritten public offering of common shares. Funding for th...

1/26/2021
DiagnosticGlaucomaNewsletterOphthalmic
Emerging Companies Pursuing Ophthalmic Indications
Emerging Companies Pursuing Ophthalmic Indications

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease. Company Location About Viridian Therapeutics Boulder, Colorado The company, formerly miRagen...

1/26/2021
DiagnosticNewsletterOphthalmicRetina
AI Algorithms Inconsistent in Detection of Diabetic Eye Disease, Study Finds
AI Algorithms Inconsistent in Detection of Diabetic Eye Disease, Study Finds

Artificial intelligence algorithms designed to detect diabetic eye disease may not perform as well as developers hoped, according to a study published Jan. 5 in Diabetes Care. Investigators tested ...

1/26/2021
NewsletterOphthalmicRefractiveSurgical
Market Scope Weekly Surgeon and Industry Polls for January 2021
Market Scope Weekly Surgeon and Industry Polls for January 2021

1/26/2021
CornealNewsletterOphthalmic
First Implanted Patient Regains Sight with CorNeat Vision’s Artificial Cornea
First Implanted Patient Regains Sight with CorNeat Vision’s Artificial Cornea

Israel’s CorNeat Vision announced Jan. 11 that its KPro artificial cornea implant restored sight in the first treated patient, a 78-year-old man. Professor Irit Bahar, MD, at Rabin Medical Center i...

Want to Read the Full Article?

Register A Corporate Account

A corporate accounts gives you access to licensed reports and subscriptions, the latest news, and a personalized dashboard.

Select one or more
Select one or more

Market Scope

13421 Manchester Road, Suite 201 | St. Louis, MO 63131 | Phone: 314-835-0600 | Email: info@market-scope.com

©2021 Market Scope, LLC. All Rights reserved.